The cellular antiviral restriction factor tetherin does not inhibit poxviral replication

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1893-1896

  Sliva, Katja ^a   Resch, Theresa ^a   Kraus, Benjamin ^a   Goffinet, Christine ^b   Keppler, Oliver T ^b   Schnierle, Barbara S ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; GLYCOPROTEIN; TETHERIN PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL LYSATE; CELL MEMBRANE; CONTROLLED STUDY; DOWN REGULATION; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; POXVIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; VACCINIA; VACCINIA VIRUS; VIRUS CELL INTERACTION; VIRUS RELEASE; VIRUS REPLICATION; VIRUS TRANSMISSION;

VACCINIA VIRUS;

EID: 84857081497     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05198-11     Document Type: Article

References (45)

1. Antoine G, Scheiflinger F, Dorner F, Falkner FG. 1998. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244:365-396.
2. Blasco R, Moss B. 1992. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 66:4170-4179.
3. Douglas JL, et al. 2010. The great escape: viral strategies to counter BST-2/tetherin. PLoS Pathog. 6:e1000913.
4. Evans DT, Serra-Moreno R, Singh RK, Guatelli JC. 2010. BST-2/tetherin: a new component of the innate immune response to enveloped viruses. Trends Microbiol. 18:388-396.
5. Goffinet C, et al. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297.
6. Gupta RK, et al. 2009. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. U. S. A. 106:20889-20894.
7. Hiller G, Weber K. 1985. Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. J. Virol. 55:651-659.
8. Hornemann S, et al. 2003. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77:8394-8407.
9. Jia B, et al. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 5:e1000429.
10. Jouvenet N, et al. 2009. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol. 83:1837-1844.
11. Kaletsky RL, Francica JR, Agrawal-Gamse C, Bates P. 2009. Tetherinmediated restriction of filovirus budding is antagonized by the Ebola glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 106:2886-2891.
12. Kraus B, Boller K, Reuter A, Schnierle BS. 2011. Characterization of the human endogenous retrovirus K Gag protein: identification of protease cleavage sites. Retrovirology 8:21.
13. Le Tortorec A, Neil SJ. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-11978.
14. Lopez LA, et al. 2010. Ebola virus glycoprotein counteracts BST-2/tetherin restriction in a sequence-independent manner that does not require tetherin surface removal. J. Virol. 84:7243-7255.
15. Mansouri M, et al. 2009. Molecular mechanism of BST2/tetherin downregulation by K5/MIR2 of Kaposi's sarcoma-associated herpesvirus. J. Virol. 83:9672-9681.
16. Mayr A, Hochstein-Mintzel V, Stickl H. 1975. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3:6-14.
17. Meiser A, Sancho C, Krijnse LJ. 2003. Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells. J. Virol. 77:9931-9942.
18. Meyer H, Sutter G, Mayr A. 1991. Mapping of deletions in the genome of the highly attenuated vaccinia virusMVAand their influence on virulence. J. Gen. Virol. 72:1031-1038.
19. Moss B. 2001. Poxviridae: the viruses and their replication, p 2849-2883. In Knipe DM, Howley PM (ed), Fields virology, 4th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
20. Moss B. 2006. Poxvirus entry and membrane fusion. Virology 344:48-54.
21. Moss B, Ward BM. 2001. High-speed mass transit for poxviruses on microtubules. Nat. Cell Biol. 3:E245-E246.
22. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430.
23. Payne LG. 1980. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 50:89-100.
24. Payne LG, Kristenson K. 1979. Mechanism of vaccinia virus release and its specific inhibition by N1-isonicotinoyl-N2-3-methyl-4-chlorobenzoylhydrazine. J. Virol. 32:614-622.
25. Radoshitzky SR, et al. 2010. Infectious Lassa virus, but not filoviruses, is restricted by BST-2/tetherin. J. Virol. 84:10569-10580.
26. Rietdorf J, et al. 2001. Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. Nat. Cell Biol. 3:992-1000.
27. Roberts KL, Smith GL. 2008. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 16:472-479.
28. Roper RL, Wolffe EJ, Weisberg A, Moss B. 1998. The envelope protein encoded by the A33R gene is required for formation of actin-containing microvilli and efficient cell-to-cell spread of vaccinia virus. J. Virol. 72: 4192-4204.
29. Sadler AJ, Williams BR. 2008. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8:559-568.
30. Sakuma T, Noda T, Urata S, Kawaoka Y, Yasuda J. 2009. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 83:2382-2385.
31. Sanderson CM, Frischknecht F, Way M, Hollinshead M, Smith GL. 1998. Roles of vaccinia virus EEV-specific proteins in intracellular actin tail formation and low pH-induced cell-cell fusion. J. Gen. Virol. 79: 1415-1425.
32. Schmelz M, et al. 1994. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 68:130-147.
33. Seet BT, et al. 2003. Poxviruses and immune evasion. Annu. Rev. Immunol. 21:377-423.
34. Sliva K, Schnierle B. 2007. From actually toxic to highly specific-novel drugs against poxviruses. Virol. J. 4:8.
35. Smith GL, Law M. 2004. The exit of vaccinia virus from infected cells. Virus Res. 106:189-197.
36. Smith GL, Murphy BJ, Law M. 2003. Vaccinia virus motility. Annu. Rev. Microbiol. 57:323-342.
37. Smith GL, Vanderplasschen A, Law M. 2002. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 83:2915-2931.
38. Tokarev A, Skasko M, Fitzpatrick K, Guatelli J. 2009. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin. AIDS Res. Hum. Retroviruses 25:1197-1210.
39. Tooze J, Hollinshead M, Reis B, Radsak K, Kern H. 1993. Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur. J. Cell Biol. 60:163-178.
40. Tsutsui K. 1983. Release of vaccinia virus from FL cells infected with the IHD-W strain. J. Electron Microsc. (Tokyo) 32:125-140.
41. Van Damme N, et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252.
42. Waibler Z, et al. 2009. Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components. J. Virol. 83: 1563-1571.
43. Yang SJ, et al. 2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13.
44. Yondola MA, et al. 2011. Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J. Virol. 85:2480-2491.
45. Zhang F, et al. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67